Trevena Inc
Company type | Public |
---|---|
Nasdaq: TRVN Russell Microcap Index component | |
Industry | Biotechnology / Pharmaceutical |
Headquarters | , United States |
Key people | Carrie L. Bourdow (President and CEO) |
Website | www |
Trevena Inc is a clinical stage
Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects.[4] Trevena's pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain, migraine, and Parkinson's disease.[5]
History
In 2008, the company raised $25 Million in a Series A[
In early 2009, Trevena entered into a collaborative agreement with
Trevena's initial public offering was on January 30, 2014.[13]
Pipeline
Oliceridine
Trevena's leading drug candidate is Oliceridine (TRV130), a G protein-biased ligand binding to the mu opioid receptor[14] for the intravenous treatment of acute moderate-to-severe post-operative pain. Phase I and II clinical trials of TRV130 for postoperative pain are complete. Phase II trials showed effectiveness is analgesia and a wider therapeutic window than morphine.[15] In February 2016, the FDA granted Breakthrough Therapy status to olicerdine.[16] In January 2017, Trevena announced that enrollment for its phase III trials, APOLLO-1 and APOLLO-2 are complete. In November 2018, Trevena received a Complete Response Letter (CRL) from FDA regarding Oliceridine and the need for additional safety data. As of late December 2018, the company has yet to release the meeting minutes from FDA on how to move forward with Oliceridine approval in 2019.
Trevena announced FDA approval of oliceridine on August 7, 2020.[17]
Trevena announced DEA scheduling, Schedule II controlled substance, of oliceridine on October 30, 2020 [18]
https://finance.yahoo.com/news/trevena-announces-publication-comprehensive-review-110010409.html
TRV027
Trevena's developed TRV027 for acute
Trevena announced it has entered into a collaboration with Imperial College London to evaluate the potential of TRV027, a novel AT1 receptor selective agonist, to treat acute lung injury contributing to acute respiratory distress syndrome (ARDS) in COVID-19 patients. ARDS is a major complication leading to mortality associated with COVID-19. Imperial College London will be sponsoring and funding this study, with additional support through the British Heart Foundation Centre for Research Excellence Award.
TRV250
TRV250 is a pre-clinical drug candidate for migraine binding to the delta opioid receptor. This avoids the addiction potential of drugs that activate the mu opioid receptor. Other delta opioid-targeting drugs are known to cause seizures,
TRV734
TRV734 is an oral follow-up to the injected TRV130 mu-opioid biased ligand program. While it binds to the same receptors as opioid analgesics, TRV734 has very weak β-arrestin recruitment, unlike other available opioids, and produced fewer off-target effects.[26] Phase I clinical trials were completed in 2014.[27]
References
- ^ "The Nobel Prize in Chemistry 2012". Nobelprize.org. 2012-10-10.
- PMID 17644195.
- ^ "Most Successful U.S. Startups 2008". Business Week. 2008-12-31. Archived from the original on December 22, 2008.
- ^ "Exploring GPCRs as Therapeutic Targets". Genetic Engineering News. 2013-04-15.
- ^ "Trevena Inc - Pipeline". Trevena Inc - Company Website. 2010-01-01.
- ^ "Trevena Inc Announces $24 Million Series A Financing". BioSpace.com. 2008-03-05.
- ^ "Trevena to Use Ligand's Library to Identify GPCR Therapeutics". Genetic Engineering News. 2009-02-06.
- ^ "Trevena Awarded $7.65 Million NIH Grant to Accelerate Identification and Selection of Biased GPCR Ligands". Business Wire. 2009-11-03.
- ^ "Refining GPCR Discovery Approaches". Genetic Engineering News. 2011-04-15.
- ^ "Trevena lands $35M round to fund its first PhII". Fierce Biotech. 2010-07-14.
- ^ "Trevena Receives Major New Award from NIH To Develop Delta Opioid Biased Ligand Drug". Business Wire. 2011-08-18.
- ^ "Pathway Validation of a Biased Delta Opioid Receptor Ligand for PD Symptoms & Side Effects Relief". Michael J. Fox Foundation. 2011-12-19.
- ^ "Investor FAQs". Trevena, Inc.
- S2CID 8785003.
- ^ "News - Trevena, Inc". www.trevena.com.
- ^ "Oliceridine injection - Trevena, Inc". www.trevena.com.
- ^ "FDA approves Trevena's Olinvyk opioid for intravenous use in hospitals (NASDAQ:TRVN) | Seeking Alpha".
- ^ "Trevena, Inc. Announces DEA Scheduling of OLINVYK™ (Oliceridine) injection". 30 October 2020.
- S2CID 10997323.
- PMID 21835984.
- ^ "Trevena Initiates Clinical Development of TRV120027, a First-in-Class Biased Ligand". Pipeline Review. 2010-04-14.
- ^ "Trevena Initiates Phase 2 Study of TRV120027 for Acute Heart Failure". Pennsylvania BioWatch. 2011-02-23.
- ^ "News - Trevena, Inc". www.trevena.com.
- ^ "Info" (PDF). www.trevena.com. 2002. Retrieved 2019-06-02.
- ^ "TRV250 - Trevena, Inc". www.trevena.com.
- ^ "TRV734 - Trevena, Inc". www.trevena.com.
- ^ "Search of: trv734 - List Results - ClinicalTrials.gov". clinicaltrials.gov.